Rapid & comprehensive comparison of five versions of bevacizumab: Avastin versus its biosimilars (Protein Metrics)
Introduction
As the pace of biosimilar development and commercialization increases, there is a clear need for LC–MS analytical methods to support or disprove similarity to an originator product. Analytical scientists rely on techniques ranging from peptide mapping, to intact mass analysis, to detailed MS/MS analysis of PTMs and
sequence variants to show similarity with originator products, as well as lot to lot similarity.
As the speed and sensitivity of mass spectrometers continue to improve, there is a concomitant need for software tools to provide rapid yet detailed and robust analysis of complex MS datasets. Here we present a study showing comprehensive analysis of five different productions of a therapeutic antibody – bevacizumab (Avastin) — using the Protein Metrics suite of analysis software.